Effect of Rifaximin on Quality of Life in Patients with Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth
DOI:
https://doi.org/10.22516/25007440.1381Keywords:
Irritable bowel syndrome, intestine, quality of life, microbiotaAbstract
Introduction: Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder with a multifactorial pathophysiology, including alterations in the gut microbiota. Small intestinal bacterial overgrowth (SIBO) may coexist with IBS and exacerbate symptoms, adversely affecting quality of life.
Objective: To evaluate the impact of rifaximin therapy on quality of life in patients diagnosed with IBS and SIBO, using the validated IBS-QoL instrument and Rome IV criteria.
Methods: A quasi-experimental study was conducted at a gastroenterology center in Cartagena, Colombia, between June 2023 and January 2024. Patients with IBS diagnosed through Rome IV criteria and a positive breath test for SIBO were included. Participants received rifaximin 550 mg every 8 hours for 14 days. Quality of life was assessed before and after treatment using the IBS-QoL scale.
Results: Seventy-one patients with confirmed SIBO were enrolled. The mean age was 48.6 years, and 81.8% were women. Following treatment, a significant improvement in quality-of-life scores was observed (p <0.001), along with a reduction in major symptoms—particularly abdominal distension, bloating, and flatulence. A total of 26.7% of participants reported no improvement.
Conclusion: The study suggests that rifaximin therapy is associated with symptomatic improvement and enhanced quality of life among patients with IBS and SIBO, with the greatest benefit observed in those presenting with abdominal distension.
Downloads
References
Pontet Y, Olano C. Prevalencia de síndrome de intestino irritable en América Latina. Revista de Gastroenterología del Perú. 2021;41(3):144-149. https://doi.org/10.47892/rgp.2021.413.1154
Schmulson MJ, Puentes-Leal GA, Bustos-Fernández L, Francisconi C, Hani A, López-Colombo A, et al. Comparison of the epidemiology of disorders of gut-brain interaction in four Latin American countries: Results of The Rome Foundation Global Epidemiology Study. Neurogastroenterol Motil. 2023;35(6):e14570. https://doi.org/10.1111/nmo.14569
Gómez-Álvarez DF, Morales-Vargas JG, Rojas-Medina LM, Mújica-Oviedo SC, Camacho-López PA, Rueda-Jaimes GE. Factores sociosanitarios y prevalencia del síndrome del intestino irritable según los criterios diagnósticos de Roma III en una población general de Colombia. Gastroenterol Hepatol. 2009;32(6):395-400. https://doi.org/10.1016/j.gastrohep.2009.01.177
Scarpellini E, Giorgio V, Gabrielli M, Lauritano EC, Pantanella A, Fundarò C, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. 2009;155(3):416-420. https://doi.org/10.1016/j.jpeds.2009.03.033
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders: results of the Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. https://doi.org/10.1053/j.gastro.2020.04.014
Bourlioux P, Braesco V, Koletzko B, Guarner F. The intestine and its microflora are partners for the protection of the host. Am J Clin Nutr. 2003;78:675-683. https://doi.org/10.1093/ajcn/78.4.675
Tojo González R, Suarez Gonzalez A, Rúas Madiedo P, Mancebo Mata A, Pipa Muñiz M, Barreiro Alonso E, et al. Síndrome de intestino irritable: papel de la microbiota y probiótico-terapia. Nutr Hosp. 2015;31(Suppl 1):83-88. https://doi.org/10.3305/nh.2015.31.sup1.8713
Shah A, Talley NJ, Jones M, Kendall BJ, Koloski N, Walker MM, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190-201. https://doi.org/10.14309/ajg.0000000000000504
Mishima Y, Ishihara S. Molecular mechanisms of microbiota-mediated pathology in irritable bowel syndrome. Int J Mol Sci. 2020;21(22):8664. https://doi.org/10.3390/ijms21228664
Takakura W, Pimentel M. Small intestinal bacterial overgrowth and irritable bowel syndrome: an update. Front Psychiatry. 2020;11:664. https://doi.org/10.3389/fpsyt.2020.00664
Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115:165-178. https://doi.org/10.14309/ajg.0000000000000501
Quera R, Quigley EMM, Madrid AM. Sobrecrecimiento bacteriano intestinal: artículo de revisión. Rev Med Chile. 2005;133:1361-1370. https://doi.org/10.4067/S0034-98872005001100013
Blasco-Alonso J, Torcuato Rubio E, Pueyo Agudo E, Polo Hernández FL, Ortiz Pérez P, Martín Masot R, et al. Diagnóstico de sobrecrecimiento bacteriano mediante empleo de prueba de hidrógeno espirado en niños afectos de síndrome de intestino irritable. En: Álvarez Calatayud G, Barros García P, Blanco Rodríguez M, Blasco Alonso J, Bodas Pinedo A, Camarena Grande MC, et al (editores). Libro de Trabajos SEGHNP 2020 [Internet]. Madrid: Ergon; 2020. p. 112 [consultado el 15 de junio de 2024]. Disponible en: https://www.seghnp.org/sites/default/files/2020-09/trabajosSEGHNP2020_0.pdf
Giannella RA, Rout WR, Toskes PP. Jejunal brush border injury and impaired sugar and amino acid uptake in the blind loop syndrome. Gastroenterology. 1974;67:965-974. https://doi.org/10.1016/S0016-5085(19)32751-9
Avelar-Rodríguez D, Toro-Monjaraz EM, Ramírez-Mayans JA. Sobrecrecimiento bacteriano en el intestino delgado: una causa de dolor abdominal crónico en niños. Bol Med Hosp Infant Mex. 2019;40(2):93-98. https://doi.org/10.18233/APM40No2pp93-981781
Tuteja AK, Talley NJ, Stoddard GJ, Verne GN. Double-blind placebo-controlled study of rifaximin and lactulose hydrogen breath test in Gulf War veterans with irritable bowel syndrome. Dig Dis Sci. 2019;64(3):838-845. https://doi.org/10.1007/s10620-018-5344-5
Dolopedia. Escalas unidimensionales del dolor [Internet]. Dolopedia; 2024 [consultado el 15 de junio de 2024]. Disponible en: https://dolopedia.com/articulo/escalas-unidimensionales-del-dolor
Gómez AJ, Hidalgo P, Alvarado-Bestene J, Rodríguez-Varón A, Cáceres-Méndez EA, Medina M. Impacto en la calidad de vida por la asociación entre trastornos del sueño y síndrome de intestino irritable. Rev Colomb Gastroenterol. 2016;31(1):16-19. https://doi.org/10.22516/25007440.68
Castañeda-Sepúlveda R. Irritable bowel syndrome. Med Univ (Méx). 2010;12(46):39-46. https://doi.org/10.1016/S0739-5930(10)79444-7
WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–1409. https://doi.org/10.1016/0277-9536(95)00112-k
Liu ZJ, Wei H, Duan LP, Zhu SW, Zhang L, Wang K. Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of rifaximin. Zhonghua Yi Xue Za Zhi. 2016;96(24):1896-1902. https://doi.org/10.3760/cma.j.issn.0376-2491.2016.24.005.
Sánchez JA, Irineo AB, Bernal G. Calidad de vida relacionada con la salud en adultos con síndrome de intestino irritable en un hospital de especialidades de México: estudio transversal. Rev Esp Enferm Dig. 2017;109(4):265-272.
Yepes IJ, Múnera MN, Martelo C. Dieta baja en oligosacáridos, disacáridos, monosacáridos y polioles fermentables y calidad de vida en pacientes con síndrome de intestino irritable en Colombia. Biomédica. 2018;38(Suppl 1):54-61.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista colombiana de Gastroenterología

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

| Article metrics | |
|---|---|
| Abstract views | 1280 |
| Galley views | 2302 |
| PDF Views | 667 |
| HTML views | 0 |
| Other views | 1635 |














